Evidence map›Paper›PMID 38412839›Full record

ArticleCerebrovascular diseases (Basel, Switzerland)2025

Late Lesion Growth following Endovascular Therapy: Is 24 h Too Early to Assess Acute Infarct Size Including the Effects of Secondary Injury?

Marie Luby, Amie W Hsia, Carolyn A Lomahan, Victoria Uche, Rachel Davis, Yongwoo Kim, Sana Somani, Shannon Burton, Rainier Cabatbat, Veronica Craft and 8 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Cerebrovascular diseases (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Hyperemia detection on arterial spin labeling is associated with final infarct volume in stroke post-endovascular therapy.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2025
    Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Marie LubyNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
Amie W HsiaNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
Carolyn A LomahanNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
Victoria UcheNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
Rachel DavisNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
Yongwoo KimNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
Sana SomaniNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
Shannon BurtonNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
Rainier CabatbatNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
Veronica CraftNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
Jill B De VisNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
Malik M AdilNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
Mariam M AfzalNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
Leila C ThomasNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
William GandlerNIH, Center for Information Technology (CIT), Bethesda, Maryland, USA.
Evan S McCreedyNIH, Center for Information Technology (CIT), Bethesda, Maryland, USA.
John K LynchNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
Lawrence L LatourNIH/NINDS, Stroke Branch, Bethesda, Maryland, USA.
National Institutes of Health · USMedStar Washington Hospital Center · USCenter for Information Technology · US

Funding

CLINICAL AND IMAGING CORE SUPPORT OF ACUTE STROKE RESEARCHZICNS003044 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI LATOUR, LAWRENCE · 2015 to 2025
$32.8M
NOVEL INSIGHTS INTO CEREBRAL ISCHEMIC PATHOPHYSIOLOGY IN HUMANSZIANS003043 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI LATOUR, LAWRENCE · 2009 to 2025
$19.5M
Intramural NIH HHS Z99 NS999999
6 · The paper itself

Abstract

introductionStroke lesion volume on MRI or CT provides objective evidence of tissue injury as a consequence of ischemic stroke. Measurement of "final" lesion volume at 24-h following endovascular therapy (post-EVT) has been used in multiple studies as a surrogate for clinical outcome. However, despite successful recanalization, a significant proportion of patients do not experience favorable clinical outcome. The goals of this study were to quantify lesion growth during the first week after treatment, identify early predictors, and explore the association with clinical outcome.

methodsThis is a prospective study of stroke patients at two centers who met the following criteria: (i) anterior large vessel occlusion acute ischemic stroke, (ii) attempted EVT, and (iii) had 3T MRI post-EVT at 24-h and 5-day. We defined "early" and "late" lesion growth as ≥10 mL lesion growth between baseline and 24-h diffusion-weighted imaging (DWI) and between 24-h DWI and 5-day fluid attenuated inversion recovery imaging, respectively. Complete reperfusion was defined as >90% reduction of the volume of tissue with perfusion delay (Tmax>6 s) between pre-EVT and 24-h post-EVT. Favorable clinical outcome was defined as modified Rankin scale (mRS) of 0-2 at 30 or 90 days.

resultsOne hundred twelve patients met study criteria with median age 67 years, 56% female, median admit NIHSS 19, 54% received IV or IA thrombolysis, 66% with M1 occlusion, and median baseline DWI volume 21.2 mL. Successful recanalization was achieved in 87%, and 68% had complete reperfusion, with an overall favorable clinical outcome rate of 53%. Nearly two-thirds (65%) of the patients did not have late lesion growth with a median volume change of -0.3 mL between 24-h and 5-day and an associated high rate of favorable clinical outcome (64%). However, ∼1/3 of patients (35%) did have significant late lesion growth despite successful recanalization (87%: 46% mTICI 2b/41% mTICI 3). Late lesion growth patients had a 27.4 mL change in late lesion volume and 30.1 mL change in early lesion volume. These patients had an increased hemorrhagic transformation (HT) rate of 68% with only 1 in 3 patients having favorable clinical outcome. Late lesion growth was independently associated with incomplete reperfusion, HT, and unfavorable outcome.

conclusionApproximately 1 out of 3 patients had late lesion growth following EVT, with a favorable clinical outcome occurring in only 1 out of 3 of these patients. Most patients with no early lesion growth had no late lesion growth. Identification of patients with late lesion growth could be critical to guide clinical management and inform prognosis post-EVT. Additionally, it can serve as an imaging biomarker for the development of adjunctive therapies to mitigate reperfusion injury.

introductionStroke lesion volume on MRI or CT provides objective evidence of tissue injury as a consequence of ischemic stroke. Measurement of "final" lesion volume at 24-h following endovascular therapy (post-EVT) has been used in multiple studies as a surrogate for clinical outcome. However, despite successful recanalization, a significant proportion of patients do not experience favorable clinical outcome. The goals of this study were to quantify lesion growth during the first week after treatment, identify early predictors, and explore the association with clinical outcome.

methodsThis is a prospective study of stroke patients at two centers who met the following criteria: (i) anterior large vessel occlusion acute ischemic stroke, (ii) attempted EVT, and (iii) had 3T MRI post-EVT at 24-h and 5-day. We defined "early" and "late" lesion growth as ≥10 mL lesion growth between baseline and 24-h diffusion-weighted imaging (DWI) and between 24-h DWI and 5-day fluid attenuated inversion recovery imaging, respectively. Complete reperfusion was defined as >90% reduction of the volume of tissue with perfusion delay (Tmax>6 s) between pre-EVT and 24-h post-EVT. Favorable clinical outcome was defined as modified Rankin scale (mRS) of 0-2 at 30 or 90 days.

resultsOne hundred twelve patients met study criteria with median age 67 years, 56% female, median admit NIHSS 19, 54% received IV or IA thrombolysis, 66% with M1 occlusion, and median baseline DWI volume 21.2 mL. Successful recanalization was achieved in 87%, and 68% had complete reperfusion, with an overall favorable clinical outcome rate of 53%. Nearly two-thirds (65%) of the patients did not have late lesion growth with a median volume change of -0.3 mL between 24-h and 5-day and an associated high rate of favorable clinical outcome (64%). However, ∼1/3 of patients (35%) did have significant late lesion growth despite successful recanalization (87%: 46% mTICI 2b/41% mTICI 3). Late lesion growth patients had a 27.4 mL change in late lesion volume and 30.1 mL change in early lesion volume. These patients had an increased hemorrhagic transformation (HT) rate of 68% with only 1 in 3 patients having favorable clinical outcome. Late lesion growth was independently associated with incomplete reperfusion, HT, and unfavorable outcome.

conclusionApproximately 1 out of 3 patients had late lesion growth following EVT, with a favorable clinical outcome occurring in only 1 out of 3 of these patients. Most patients with no early lesion growth had no late lesion growth. Identification of patients with late lesion growth could be critical to guide clinical management and inform prognosis post-EVT. Additionally, it can serve as an imaging biomarker for the development of adjunctive therapies to mitigate reperfusion injury.

Indexed as

Diffusion Magnetic Resonance ImagingEndovascular ProceduresIschemic StrokeThrombolytic TherapyAgedAged, 80 and overFemaleHumansMaleMiddle AgedPredictive Value of TestsProspective StudiesTime FactorsTreatment OutcomeAcute ischemic strokeEndovascular therapyFinal infarct volumeLesion growthMRI

Identifiers

PMID38412839
PMCPMC11347714
OpenAlexW4392185974

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.